Lonza Group AG (SWX: LONN) is a Swiss contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotech industries. Specializing in biologics, cell and gene therapies, and small molecule APIs, Lonza plays a critical role in scaling complex therapies. With long-term client contracts and global facilities, the company benefits from rising biotech outsourcing and specialty medicine demand. Lonza offers investors a high-quality life sciences supplier with resilient, innovation-led growth.
最新股票文章

英伟达股票预测:第三方价格目标
自2025年年初以来,截至4月中旬,英伟达(NVDA)股价下跌约27.37%,但同比上涨26.48%。基于4月22日开盘价98.78美元,自1月初以来,英伟达股票波动显著,受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025


